[Omaron in the restorative treatment of patients with chronic cerebrovascular insufficiency].
Stroganova
I M
IM
Kiparisov
M A
MA
D000284:Administration, Oral; D050197:Atherosclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D002560:Cerebrovascular Circulation / Q000502:physiology*; D002908:Chronic Disease; D002936:Cinnarizine / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use*; D020127:Recovery of Function; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler; D014711:Vertebral Artery / Q000000981:diagnostic imaging
D002121:Calcium Channel Blockers; D004338:Drug Combinations; D018696:Neuroprotective Agents; D002936:Cinnarizine; D010889:Piracetam